Comprehensive Assessment of Risk-Based Quality Management Adoption in Clinical Trials
Therapeutic Innovation & Regulatory Science · 2024-05 · 58 (3) · 520-527
DOI: 10.1007/s43441-024-00618-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 16.02.2024. Verfasst von Abigail Dirks und 5 weiteren Autor:innen. Beteiligte Einrichtung: Tufts Center for the Study of Drug Development, Tufts School of Medicine, Boston, MA, USA. abigail.dirks@tufts.edu. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Risk Management. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CluePoints, Price Waterhouse Coopers.
Abstract (Originalsprache)
Background
Risk-based monitoring (RBM) and risk-based quality management (RBQM) offer a compelling approach to increase efficiency, speed and quality in clinical trials by prioritizing and mitigating risks related to essential safety and efficacy data. Since 2013, the FDA and EMA have encouraged the use of RBM/RBQM, however adoption has been slow with limited understanding of the barriers to adoption.
Methods
The Tufts Center for the Study of Drug Development conducted an online survey among pharmaceutical, biotechnology, and contract research organizations and gathered 206 responses on 32 distinct RBQM practices.
Results
On average, companies implemented RBQM in 57% of their clinical trials. Lower levels of adoption were observed among companies conducting fewer than 25 trials annually (48%) compared to those conducting more than 100 trials annually (63%). Primary barriers to adoption include lack of organizational knowledge and awareness, mixed perceptions of the value proposition of RBQM, and poor change management planning and execution. Insights into improving the level of adoption are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tufts Center for the Study of Drug Development, Tufts School of Medicine, Boston, MA, USA. abigail.dirks@tufts.edu.
- Tufts Center for the Study of Drug Development, Tufts School of Medicine, Boston, MA, USA.
- CluePoints, Brussels, Belgium.
- Price Waterhouse Coopers (PWC), London, United Kingdom.
ORCID-Profile: Abigail Dirks
Förderung
- CluePoints
- Price Waterhouse Coopers
Zitieren
APA
Dirks, A., Florez, M., Torche, F., Young, S., Slizgi, B., & Getz, K. (2024). Comprehensive Assessment of Risk-Based Quality Management Adoption in Clinical Trials. Therapeutic Innovation & Regulatory Science, 58(3), 520-527. https://doi.org/10.1007/s43441-024-00618-5
Vancouver
Dirks A, Florez M, Torche F, Young S, Slizgi B, Getz K. Comprehensive Assessment of Risk-Based Quality Management Adoption in Clinical Trials. Therapeutic Innovation & Regulatory Science. 2024;58(3):520-527. doi:10.1007/s43441-024-00618-5
BibTeX
@article{Dirks2024,
author = {Dirks, Abigail and Florez, Maria and Torche, Francois and Young, Steve and Slizgi, Brian and Getz, Kenneth},
title = {Comprehensive Assessment of Risk-Based Quality Management Adoption in Clinical Trials},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2024},
volume = {58},
number = {3},
pages = {520--527},
doi = {10.1007/s43441-024-00618-5}
}
EUVIMED